Phase I Study on the Efficacy of Senicapoc and Perampanel in Newly Diagnosed Glioblastoma Treatment

The primary objective of this early-stage clinical trial is to evaluate the individual and combined effects of senicapoc and perampanel in patients with newly diagnosed glioblastoma. This investigation aims to determine the therapeutic potential of these agents in managing this aggressive brain tumor. 3, 5

The sponsor did not provide information regarding the total number of participants. The study population consists of patients diagnosed with glioblastoma. The cohort includes both male and female individuals. Based on the provided age range codes, the participants fall within specific pediatric or adolescent age groups. No further information regarding lifestyle considerations or specific selection processes was disclosed.

This Phase 3 clinical trial is designed to investigate the individual and combined effects of senicapoc and perampanel in the treatment of newly diagnosed glioblastoma. The study utilizes a specific research methodology to evaluate these pharmacological agents. The sequence of procedures begins with a screening visit to assess eligibility. Subsequent follow-up visits are conducted to monitor clinical progress, concluding with an end-of-study visit. The total duration of the trial is estimated to span from January 1, 2026, to November 1, 2028. Participant involvement is subject to specific conditions that may necessitate early termination from the study.

The efficacy assessment in this phase 3 clinical trial for glioblastoma is not specified in the provided documentation.